Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model

Nanomedicine

Volumn 4, Issue 2, 2009, Pages 135-143

  Zeisser Labouèbe, Magali ^a,b   Delie, Florence ^a,b   Gurny, Delie ^a,b   Lange, Norbert ^a,b  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cancer; Chorioallantoic membrane; Drug delivery system; Fluorescence photodetection; Hypericin; In vivo; Nanoparticle; Screening

Indexed keywords

FLUORESCENT DYE; HYPERICIN; NANOPARTICLE; POLYLACTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CHICK; CHORIOALLANTOIC MEMBRANE MODEL; CHORIOALLANTOIS; CONTRAST MEDIUM EXTRAVASATION; DRUG DELIVERY SYSTEM; EMBRYO; FEMALE; FLUORESCENCE ANGIOGRAPHY; MODEL; NONHUMAN; OVARY METASTASIS; PARTICLE SIZE; PRIORITY JOURNAL; TUMOR LOCALIZATION; TUMOR VASCULARIZATION; ZETA POTENTIAL;

ANIMALS; CELL LINE, TUMOR; CHICK EMBRYO; CHICKENS; CHORIOALLANTOIC MEMBRANE; EARLY DETECTION OF CANCER; FEMALE; FLUORESCENCE; NANOPARTICLES; OVARIAN NEOPLASMS; PERYLENE; RATS;

EID: 67649979495     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.4.2.135     Document Type: Article

References (42)

1. Wagnières GA, Star WM, Wilson BC: In vivo fluorescence spectroscopy and imaging for oncological applications. Photochem. Photobiol.68(5),603-632 (1998).
2. Allison RR, Cuenca R, Downie GH, Randall ME, Bagnato VS, Sibata CH: PD/ PDT for gynecological disease: a clinical review. Photodiagn. Photodyn. Ther.2,51-63 (2005).
3. Castano AP, Demidova TN, Hamblin MR: Mechanisms in photodynamic therapy: part three-photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagn. Photodyn. Ther.2(2),91-106 (2005).
4. D'Hallewin MA, Bezdetnaya L, Guillemin F: Fluorescence detection of bladder cancer: a review. Eur. Urol.42(5),417-425 (2002).
5. Jocham D, Stepp H, Waidelich R: Photodynamic diagnosis in urology: state-of-the-art. Eur. Urol.53(6),1138-1150 (2007).
6. Zeisser-Labouèbe M, Lange N, Gumy R, Delie F: Hypericin-loaded nanoparticles for the photodynamic treatment of ovarian cancer. Int. J. Pharm. 326(1-2),174-181 (2006).
7. Agostinis P, Vantieghem A, Merlevede W, De Witte PAM: Hypericin in cancer treatment: more light on the way. Int. J. Biochem. Cell Biol.34(3),221-241 (2002).
8. Kamuhabwa A, Agostinis P, Ahmed B et al.: Hypericin as a potential phototherapeutic agent in superficial transitional cell carcinoma of the bladder. Photochem. Photobiol. Sci.3(8),772-780 (2004).
9. Saw CL, Olivo M, Soo KC, Heng PW: Delivery of hypericin for photodynamic applications. Cancer Lett.241(1),23-30 (2005).
10. Zeisser-Labouèbe M, Vargas A, Delie F: Nanoparticles for photodynamic therapy of cancer. In: Nanomaterials for Cancer Therapy. Kumar CS (Ed.). Wiley-VCH Weinheim, Germany (2006).
11. Zeisser-Labouèbe M, Delie F, Gurny R, Lange N: Benefits of nanoencapsulation for the hypericin-mediated photodetection of ovarian micrometastases. Eur. J. Pharm. Biopharm. (2008) (Epub ahead of print).
12. Ribatti D, Vacca A, Roncali L, Dammacco F: The chick embryo chorioallantoic membrane as a model for in vivo research on angiogenesis. Int. J. Dev. Biol.40(6),1189-1197 (1996).
13. Richardson M, Singh G: Observations on the use of the avian chorioallantoic membrane (CAM) model in investigations into angiogenesis. Curr. Drug Targets Cardiovasc. Haematol. Disord.3(2),155-185 (2003).
14. Klueh U, Dorsky DI, Moussy F, Kreutzer DL: Ex ova chick chorioallantoic membrane as a novel model for evaluation of tissue responses to biomaterials and implants. J. Biomed. Mater. Res. A67(3),838-843 (2003).
15. Valdes TI, Kreutzer D, Moussy F: The chick chorioallantoic membrane as a novel in vivo model for the testing of biomaterials. J. Biomed. Mater. Res. A62(2),273-282 (2002).
16. Valdes TI, Klueh U, Kreutzer D, Moussy F: Ex ova chick chorioallantoic membrane as a novel in vivo model for testing biosensors. J. Biomed. Mater. Res. A67(1),215-223 (2003).
17. Gottfried V, Lindenbaum ES, Kimel S: The chick chorioallantoic membrane (CAM) as an in vivo model for photodynamic therapy. J. Photochem. Photobiol. B12(2),204-207 (1992).
18. Vargas A, Zeisser-Labouebe M, Lange N, Gurny R, Delie F: The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv. Drug Deliv. Rev.59(11),1162-1176 (2007).
19. Ribatti D: The first evidence of the tumor-induced angiogenesis in vivo by using the chorioallantoic membrane assay dated 1913. Leukemia18(8),1350-1351 (2004).
20. Chin WW, Heng PW, Olivo M: Chlorin e6-polyvinylpyrrolidone mediated photosensitization is effective against human non-small cell lung carcinoma compared with small cell lung carcinoma xenografts. BMC Pharmacol.7,15 (2007).
21. Chin WWL, Lau WKO, Bhuvaneswari R, Heng PWS, Olivo M: Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model. Cancer Lett.245(1-2),127-133 (2007).
22. Saw CL, Olivio M, Chin WW, Soo KC, Heng PW: Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model. J. Photochem. Photobiol. B86(3),207-218 (2006).
23. Lange N, Ballini JP, Wagnieres G, van den Bergh H: A new drug-screening procedure for photosensitizing agents used in photodynamic therapy for CNV. Invest. Ophthalmol. Vis. Sci.42(1),38-46 (2001).
24. Rose GS, Tocco LM, Granger GA et al. : Development and characterization of a clinically useful animal model of epithelial ovarian cancer in the Fischer 344 rat. Am. J. Obstet. Gynecol. 175(3 Pt 1),593-599 (1996).
25. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC: Models of ovarian cancer - are we there yet? Mol. Cell. Endocrinol.239(1-2),15-26 (2005).
26. Marti A, Lange N, van den Bergh K Sedmera D, Jichlinski P, Kucera P: Optimization of the formation and distribution of protoporphyrin IX in the urothelium: an in vitro approach. J. Urol. 162(2),546-552 (1999).
27. Lange N, Vaucher L, Marti A et al. : Routine experimental system for defining conditions used in photodynamic therapy and fluorescence photodetection of (non-) neoplastic epithelia. J. Biomed. Opt.6(2),151-159 (2001).
28. Sale S, Orsulic S: Models of ovarian cancer metastasis: murine models. Drug Discov. Today Dis. Models3(2),149-154 (2006).
29. Teicher BA: Tumor models for efficacy determination. Mol. Cancer. Ther. 5(10),2435-2443 (2006).
30. Frese KK, Tuveson DA: Maximizing mouse cancer models. Nat. Rev. Cancer7(9),645-658 (2007).
31. Brigger I, Dubernet C, Couvreur P: Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev.54(5),631-651 (2002).
32. Takakura Y, Mahato RI, Hashida M: Extravazation of macromolecules. Adv. Drug Deliv. Rev.34(1),93-108 (1998).
33. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Rel.65(1-2),271-284 (2000).
34. Maeda H, Fang J, Inutsuka T, Kitamoto Y: Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol.3(3),319-328 (2003).
35. Iyer AK, Khaled G, Fang J, Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today11(17-18),812-818 (2006).
36. Pegaz B, Debefve E, Borle F, Ballini JP, van den Bergh H, Kouakou-Konan YN: Encapsulation of porphyrins and chlorins in biodegradable nanoparticles: the effect of dye lipophilicity on the extravazation and the photothrombic activity. A comparative study. J. Photochem. Photobiol. B80(1),19-27 (2005).
37. Pegaz B, Debefve E, Ballini JP et al. : Photothrombic activity of m-THPC-loaded liposomal formulations: Pre-clinical assessment on chick chorioallantoic membrane model. Eur. J. Pharm. Sci.28(1-2),134-140 (2006).
38. Pegaz B, Debefve E, Ballini JP, Konan-Kouakou YN, van den Bergh H: Effect of nanoparticle size on the extravazation and the photothrombic activity of meso(p-tetracarboxyphenyl)porphyrin. J. Photochem. Photobiol. B85,216-222 (2006).
39. Vargas A, Eid M, Fanchaouy M, Gurny F, Delie F: In vivo photodynamic activity of photosensitizer-loaded nanoparticles: Formulation properties, administration parameters and biological issues involved in PDT outcome. Eur. J. Pharm. Biopharm.69(1),43-53 (2008).
40. Fotinos N, Campo MA, Popowycz F, Gurny F, Lange N: The chick embryo model for the evalution of 5-aminolevulinic acid derivatives. Photochem. Photobiol.82(4) 994-1015 (2006).
41. Gottfried V, Davidi F, Averguj C, Kimel S: In vivo damage to chorioallantoic membrane blood vessels by porphycene-induced photodynamic therapy. J. Photochem. Photobiol. B30(2-3),115-121 (1995).
42. Ismail MS, Torsten U, Dressler C et al. : Photodynamic therapy of malignant ovarian tumors cultivated on CAM. Lasers Med. Sci. 14(2),91-96 (1999).